Annual report pursuant to Section 13 and 15(d)

Segment Information (Tables)

v3.24.1.u1
Segment Information (Tables)
12 Months Ended
Dec. 30, 2023
Segment Reporting [Abstract]  
Schedule of Segment Information
The following tables present our segment information (in $000’s):
For the Years Ended
December 30, 2023 December 31, 2022
Revenues
Biotechnology $ —  $ — 
Discontinued operations 3,795  39,611 
Total Revenues $ 3,795  $ 39,611 
Gross profit
Biotechnology $ —  $ — 
Discontinued operations (197) 7,619 
Total Gross profit $ (197) $ 7,619 
Operating income
Biotechnology $ (19,846) $ (3,149)
Discontinued operations 10,438  8,395 
Total Operating income $ (9,408) $ 5,246 
Depreciation and amortization
Biotechnology $ 1,452  $
Discontinued operations 96  555 
Total Depreciation and amortization $ 1,548  $ 557 
Interest income (expense), net
Biotechnology $ 2,250  $ 468 
Discontinued operations (181) (957)
Total Interest income (expense), net $ 2,069  $ (489)
Net income after provision for income taxes
Biotechnology $ (17,095) $ 8,020 
Discontinued operations 9,283  2,972 
Total Net income after provision for income taxes $ (7,812) $ 10,992 
As of
December 30, 2023
As of
December 31, 2022
Assets
Biotechnology $ 18,487  $ 29,165 
Discontinue operations —  17,591 
Total Assets $ 18,487  $ 46,756 
Intangible Assets
Biotechnology $ 17,846  $ 19,297 
Discontinued operations —  735 
Total Intangible Assets $ 17,846  $ 20,032